Press release
Diabetic Kidney Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight
"Diabetic Kidney Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Kidney Disease Market.
The Diabetic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Diabetic Kidney Disease Pipeline Report: https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Diabetic Kidney Disease treatment therapies with a considerable amount of success over the years.
• Diabetic Kidney Disease companies working in the treatment market are Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others, are developing therapies for the Diabetic Kidney Disease treatment
• Emerging Diabetic Kidney Disease therapies in the different phases of clinical trials are- ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others are expected to have a significant impact on the Diabetic Kidney Disease market in the coming years.
• In April 2025, A recent study led by Sankar D. Navaneethan and colleagues, published in the International Society of Nephrology, demonstrated that the cardiovascular and kidney benefits of Bayer's Kerendia (finerenone) remain consistent, regardless of initial acute changes in estimated glomerular filtration rate (eGFR) after starting treatment in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
• In November 2024, At the American Heart Association (AHA) conference, during a key session titled "GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics," Dr. Katherine Tuttle explored the renal benefits of glucagon-like peptide-1 (GLP-1) receptor agonist therapy. She specifically highlighted Novo Nordisk's Ozempic (semaglutide), emphasizing its role in advancing GLP-1 treatments for managing diabetic kidney disease.
• In March 2024, Hua Medicine, based in China, intends to prioritize the development of its type 2 diabetes (T2D) medication for diabetic kidney patients in the United States. According to George Lin, the Chief Strategy Officer, the company aims to initiate clinical trials specifically tailored for the US market, focusing on creating a once-daily formulation of their drug Huatangning (dorzagliatin).
Diabetic Kidney Disease Overview
Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a complication of diabetes characterized by damage to the kidneys' filtering units, known as nephrons. It is a common complication of both type 1 and type 2 diabetes. Over time, high levels of blood sugar can damage the blood vessels and filtration system in the kidneys, leading to impaired kidney function.
Get a Free Sample PDF Report to know more about Diabetic Kidney Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Diabetic Kidney Disease Drugs Under Different Phases of Clinical Development Include:
• ORBCEL-M: Orbsen Therapeutics
• DMX-200: Dimerix Bioscience
• INV-202: Inversago Pharma
• CSL346: CSL Behring
• Bardoxolone methyl: Kyowa kirin
Diabetic Kidney Disease Pipeline Therapeutics Assessment
• Diabetic Kidney Disease Assessment by Product Type
• Diabetic Kidney Disease By Stage and Product Type
• Diabetic Kidney Disease Assessment by Route of Administration
• Diabetic Kidney Disease By Stage and Route of Administration
• Diabetic Kidney Disease Assessment by Molecule Type
• Diabetic Kidney Disease by Stage and Molecule Type
DelveInsight's Diabetic Kidney Disease Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Diabetic Kidney Disease product details are provided in the report. Download the Diabetic Kidney Disease pipeline report to learn more about the emerging Diabetic Kidney Disease therapies
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Diabetic Kidney Disease Therapeutics Market include:
Key companies developing therapies for Diabetic Kidney Disease are - AstraZeneca, Pfizer Inc., Novartis AG, Bayer AG, Sanofi Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical, and others.
Diabetic Kidney Disease Pipeline Analysis:
The Diabetic Kidney Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Kidney Disease Treatment.
• Diabetic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Kidney Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Kidney Disease drugs and therapies
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Diabetic Kidney Disease Pipeline Market Drivers
• Increasing prevalence of diabetes worldwide, rising geriatric population, increasing demand of novel therapies are some of the important factors that are fueling the Diabetic Kidney Disease Market.
Diabetic Kidney Disease Pipeline Market Barriers
• However, lack of skilled professionals to treat diabetic kidney disease in less developed countries, stringent regulatory guidelines and other factors are creating obstacles in the Diabetic Kidney Disease Market growth.
Scope of Diabetic Kidney Disease Pipeline Drug Insight
• Coverage: Global
• Key Diabetic Kidney Disease Companies: Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others
• Key Diabetic Kidney Disease Therapies: ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others
• Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies
• Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Kidney Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight here
News-ID: 4348574 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Diabetic
Exploring The Diabetic Retinopathy Market In A Diabetic-Prevalent World: The Dri …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Diabetic Retinopathy Market Size Growth Forecast: What to Expect by 2025?
The diabetic retinopathy market has experienced robust expansion over the last few years, with projections indicating a rise from $8.61 billion in 2024 next year to $9.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of…
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
